IQVIA

Market Reflection Report

Aug 2022

10th Aug 2022

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM Overview
SSA
TSA
Growth %%

80 60
60 2019-20 40
40
2020-21 20
20
0 2021-22 0
-20 -20
Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug

TSA IPM Trends (Value Rs. 187,955 Crs) – MAT Aug'22 SSA IPM Trends (Value Rs. 159,325 Crs) – MAT Aug'22
Growth Over Previous Month – Aug'22 over Jul’22 5.46% Growth Over Previous Month – Aug'22 over Jul’22 5.09%

+10%
7% +9%
MAT MAT 7%
Month 187,955 Month
175,571 159,325
149,023

149,003
142,705 127,153
120,677

13,514 13,467 16,019 17,575 11,588 13,610 14,896

11,447

2019 2020 2021 2022 2019 2020 2021 2022

• IPM- TSA valued at Rs.187,955 Cr with growth of 7% as of MAT Aug’22 and Rs 17,575 Cr for Aug’22 month with growth of 10%
• SSA valued at Rs. 159,325 Cr with growth of 7% as of MAT Aug’22 and Rs 14,896 Cr for Aug’22 month with growth of 9%

IQVIA TSA & SSA Dataset Aug’22 1

 Gastro followed by Gynae posted highest growth in top 10
therapies for Aug’22
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)
21
13 10 12 10 14 8 10
4 5
IPM 17,575 -9 -6 IPM
28 21 50
17 13 4 -6 19 10 11 AI
ANTI-INFECTIVES 2,286 -30 -28
12 10 8 10 11
6 6 7 5 7
CARDIAC 2,011 -4 -4 CARDIAC

10 11 17 11 15 12 20 12 14
3 9 8
GASTRO 1,874 GASTRO
10 9 8 8 8
6 6 5 7
ANTI DIABETIC 1,524 1 3 1 ADB
58 86
36 24 33 16 11 18 16 8 RESP
-24 -30 25
RESPIRATORY 1,471
19 16 19 14 28 14
4 8 -2 11 12
PAIN
PAIN 1,449
16
3 9 7 6 8 5 7
1 2 VMN
VMN 1,395
-13 -14
6 6 5 5
4 3 4
2 2 2 1
DERMA 1,220 DERMA
-3
11 15 15 14
10 8 9 9 9 8 11
NEURO 1,018 4 NEURO
17 20 30 22
15 9 11 9 3 10 9 14
GYNAE
GYNAEC. 885
Sep Oct Nov Dec Jan Feb Feb Apr May Jun Jul Aug

Therapy sorted on Month

IQVIA TSA & SSA Dataset Aug’22 2
 Top Companies #1-10 Market Share Trend
9

Val Aug’22 MS Aug’22

8 (SUN*) 1327 7.55
ABBOTT* 1086 6.18
7 CIPLA 896 5.10
MANKIND 801 4.56
ALKEM* 758 4.31
6
MACLEODS 601 3.42
(INTAS*) 590 3.36
5
(LUPIN) 588 3.35
(TORRENT) 554 3.15
4 (DRL) 519 2.96

2
Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22

• Cipla, Mankind, Alkem & Macleods shown improvement in MS for Aug’22 as compared to Jul’22
• Abbott* has maintained MS in the month of Aug’22
• Sun* ,Intas*, Lupin, Torrent & DRL reflected dip in MS for Aug’22 as c ompared to Jul’22

IQVIA TSA & SSA Dataset Aug'22 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,327 14 104 SUN* 1,135 13 103

ABBOTT* 1,086 12 102 ABBOTT* 926 13 103
CIPLA 896 11 101 CIPLA 749 12 103
MANKIND 801 10 100 MANKIND 724 10 101
Month

Month
ALKEM* 758 16 105 ALKEM* 656 16 106
MACLEODS 601 17 107 MACLEODS 531 16 106
INTAS* 590 17 107 LUPIN 503 7 97

LUPIN 588 8 99 TORRENT 486 14 104

TORRENT 554 15 105 INTAS* 483 16 106

5 96 ARISTO* 468 3 94
DRL 519

SUN* 14,442 12 105 SUN* 12,379 11 104

ABBOTT* 11,674 10 102 ABBOTT* 9,951 9 102
CIPLA 9,782 3 96 CIPLA 8,209 6 100
MANKIND 8,017 9 102 MANKIND 7,219 8 101
MAT

104 104

MAT
ALKEM* 7,442 12 ALKEM* 6,499 11
LUPIN 6,640 7 100 LUPIN 5,743 6 99
INTAS* 6,290 14 107 MACLEODS 5,383 12 105
TORRENT 6,091 12 104 TORRENT 5,380 11 104
MACLEODS 6,047 13 105 INTAS* 5,166 13 106
DRL 5,673 4 98 ARISTO* 4,956 9 102

• TSA: Macleods has posted highest growth for the month followed by Intas while for MAT, Intas* followed by Macleods posted highest growth

• SSA: Intas* has posted highest growth for the month followed by Alkem* and for MAT Intas* followed by Macleods has posted highest growth

4
IQVIA TSA & SSA Dataset Aug'22
 Top Companies #11-20 Market Share Trend
3.4

3.2
Val Aug’22 MS Aug’22
3.0
ARISTO* 518 2.95
2.8 ZYDUS* 505 2.88
2.6 GSK* 476 2.71
2.4 EMCURE* 361 2.05
2.2 GLENMARK 361 2.05
2.0 IPCA 332 1.89
(U S V) 326 1.85
1.8
MICRO * 310 1.76
1.6
PFIZER* 285 1.62
1.4
(SANOFI*) 271 1.54
1.2

1.0

0.8

0.6
Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22

• Aristo*, Zydus, GSK*, Emcure*, Glenmark, IPCA, Micro* & Pfizer* have shown improvement in MS for Aug’22 as compared to Jul’22
• USV & Sanofi* reflected dip in MS for Aug’22 as compared to Jul’22
.

IQVIA TSA & SSA Dataset Aug'22 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

4 95 DRL 447 3 94
ARISTO* 518
11 101 ZYDUS* 416 12 103
ZYDUS* 505
10 100 GSK* 393 13 104
GSK* 476
7 98 GLENMARK 318 11 102
EMCURE* 361
Month

Month
9 99 EMCURE* 299 11 101
GLENMARK 361
10 100 USV 292 14 104
IPCA 332
12 102 IPCA 287 8 99
USV 326
6 97 MICRO * 269 9 100
MICRO * 310
-4 88 ALEMBIC 239 6 97
PFIZER* 285
1 92 PFIZER* 223 -3 89
SANOFI* 271

ZYDUS* 5,470 6 99 DRL 4,903 5 98

ARISTO* 5,463 9 102 ZYDUS* 4,459 6 99
GSK* 4,834 5 98 GSK* 3,879 6 99
GLENMARK 3,933 -9 85 GLENMARK 3,454 -9 85
MAT

97 9 102

MAT
EMCURE* 3,897 3 USV 3,231
USV 3,628 7 100 EMCURE* 3,174 6 99
IPCA 3,423 15 107 IPCA 2,954 13 106
PFIZER* 3,260 -3 90 MICRO * 2,701 13 106
MICRO * 3,216 14 106 ALEMBIC 2,558 9 102
SANOFI* 3,119 1 95 PFIZER* 2,508 -3 90

• TSA: USV posted highest growth for the month followed by Zydus, for MAT, Ipca followed by Micro* posted highest growth

• SSA: USV posted highest growth for the month followed by GSK*, for MAT, Ipca followed by Micro* posted highest growth

IQVIA TSA & SSA Dataset Aug'22 6

 Top Companies #21-30 Market Share Trend
1.8
Val Aug’22 MS Aug’22
1.7
(ALEMBIC) 266 1.51
1.6 (FDC) 177 1.01
1.5 JB PHARMA* 175 1.00
1.4 (ERIS*) 142 0.81
HIMALAYA 137 0.78
1.3
(CADILA) 132 0.75
1.2
FRANCO 130 0.74
1.1
(AJANTA) 121 0.69
1.0 (INDOCO*) 120 0.68
0.9 BLUE CROSS 118 0.67

0.8

0.7

0.6

0.5
Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22

• Blue Cross has shown improvement in MS for Aug’22 as compared to Jul’22

• JB Pharma*, Himalaya & Franco have maintained MS in the month of Aug’22
• Alembic, FDC, Eris*, Cadila, Ajanta & Indoco* reflected dip in MS for Aug’22 as compared to Jul’22

IQVIA TSA & SSA Dataset Aug'22 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

98 SANOFI* 210 4 95
ALEMBIC 266 8
100 FDC 163 10 100
FDC 177 10
20 109 JB PHARMA* 154 20 110
JB PHARMA* 175
11 101 ERIS* 123 10 101
ERIS* 142
Month

Month
4 95 HIMALAYA 122 3 94
HIMALAYA 137
5 96 FRANCO 120 -1 90
CADILA 132
0 91 INDOCO* 109 7 98
FRANCO 130
9 99 CADILA 108 4 95
AJANTA 121
7 98 AJANTA 108 9 99
INDOCO* 120
6 97 BLUE CROSS 107 5 96
BLUE CROSS 118

ALEMBIC 2,834 10 103 SANOFI* 2,390 1 94

FDC 1,854 6 99 FDC 1,701 6 99
JB PHARMA* 1,708 19 111 JB PHARMA* 1,505 18 110
ERIS* 1,591 8 101 HIMALAYA 1,423 -2 92
MAT

93 6 99

MAT
HIMALAYA 1,587 -1 ERIS* 1,373
CADILA 1,450 3 97 FRANCO 1,252 -3 91
AJANTA 1,365 14 106 AJANTA 1,215 13 106
FRANCO 1,345 -2 92 CADILA 1,187 0 94
INDOCO* 1,246 8 101 INDOCO* 1,134 7 100
BLUE CROSS 1,163 10 103 BLUE CROSS 1,064 10 103

• TSA & SSA: JB Pharma* has posted highest growth for the month followed by Eris* and for MAT JB Pharma* has posted highest growth followed by Ajanta

IQVIA TSA & SSA Dataset Aug'22 8

 Top Companies #31-40 Market Share Trend
0.68 Val Aug’22 MS Aug’22
0.66
(LA RENON) 105 0.60
0.64
P&G HLTH 100 0.57
0.62
0.60 HETERO* 98 0.56
0.58 (MEDLEY) 96 0.55
0.56 (CORONA) 94 0.53
0.54 (NOVARTIS*) 90 0.51
0.52 (SYSTOPIC) 87 0.50
0.50
WIN MEDICARE 82 0.47
0.48
H&H 80 0.45
0.46
0.44
APEX 80 0.45
0.42
0.40
0.38
0.36
0.34
Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22

• Hetero*, H&H & Apex have shown improvement in MS for Aug’22 as compared to Jul’22
• P & G, Win Medicare have maintained MS in the month of Aug’22
• La Renon, Medley, Corona, Novartis* & Systopic reflected dip in MS for Aug’22 as compared to Jul’22

IQVIA TSA & SSA Dataset Aug'22

9
 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

LA RENON 105 32 120 P&G HLTH 91 20 109

P&G HLTH 100 20 109 MEDLEY 90 11 102
HETERO* 98 4 95 LA RENON 86 35 124
MEDLEY 96 11 101 HETERO* 80 4 95
Month

Month
CORONA 94 15 104 CORONA 79 15 105
NOVARTIS* 90 14 103 SYSTOPIC 78 8 99
SYSTOPIC 87 9 99 WIN MEDICARE 71 10 100
WIN MEDICARE 82 11 101 APEX 71 17 107
H&H 80 11 101 NOVARTIS* 70 12 103
APEX 80 18 108 H&H 70 11 101

P&G HLTH 1,116 13 105 P&G HLTH 1,028 13 105

LA RENON 1,088 32 123 MEDLEY 908 5 98
NOVARTIS* 1,022 -2 92 LA RENON 879 34 125
HETERO* 972 -13 82 SYSTOPIC 852 8 101
MAT

98 17 110

MAT
MEDLEY 968 5 CORONA 813
CORONA 964 16 108 NOVARTIS* 795 0 93
SYSTOPIC 949 8 101 HETERO* 789 -6 87
H&H 844 11 104 H&H 741 10 103
WIN MEDICARE 840 0 93 WIN MEDICARE 726 -1 93
BHARAT SERUM 822 6 99 APEX 692 -7 87

• TSA & SSA: La Renon shows the highest growth for the month followed by P&G while for MAT La Renon has posted highest growth followed by Corona

IQVIA TSA & SSA Dataset Aug'22 10

 Top Companies #41-50 Market Share Trend
0.54
0.52 Val Aug’22 MS Aug’22
0.50 JANSSEN 76 0.43
0.48 (WALLACE) 71 0.40
0.46 FOURRTS 71 0.40
0.44 (MEYER) 67 0.38
0.42 (BHARAT SERUM) 65 0.37
0.40 (RAPTAKOS) 65 0.37
0.38 (MSD*) 62 0.35
0.36 (BOEHRINGER) 60 0.34
0.34 ASTRA 57 0.32
0.32
(CENTAUR) 53 0.30
0.30
0.28
0.26
0.24
0.22
Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22

• Astra has shown improvement in MS for Aug’22 as compared to Jul’22

• Janssen & Fourrts has maintained MS in the month of Aug’22
• Wallace, Meyer, Bharat Serum, MSD*, Boehringer & Centaur reflected dip in MS for Aug’22 as compared to Jul’22

IQVIA TSA & SSA Dataset Aug'22 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

WALLACE 64 13 104
JANSSEN 76 25 114
FOURRTS 61 9 99
WALLACE 71 13 103
MEYER 58 2 93
FOURRTS 71 9 100
RAPTAKOS 57 12 103
MEYER 67 1 92
Month

Month
JANSSEN 52 9 100
BHARAT SERUM 65 -8 84
BOEHRINGER 50 -6 86
RAPTAKOS 65 13 103
CENTAUR 49 -2 90
MSD* 62 -12 80
BHARAT SERUM 47 -14 79
BOEHRINGER 60 -4 88
MSD* 46 -11 81
ASTRA 57 30 118
PHARMED 41 8 99
CENTAUR 53 0 91

JANSSEN 780 25 117 FOURRTS 665 5 99

APEX 779 -5 88 WALLACE 658 8 101
MSD* 769 -20 75 BOEHRINGER 639 -3 91
FOURRTS 764 5 98 MEYER 628 6 99
MAT

1 95

MAT
BOEHRINGER 761 -2 91 BHARAT SERUM 600
MEYER 734 6 99 RAPTAKOS 589 -3 91
WALLACE 731 8 101 MSD* 583 -21 74
RAPTAKOS 664 -1 92 JANSSEN 559 12 105
CENTAUR 584 11 104 CENTAUR 546 10 103
DABUR 573 -4 89 PHARMED 457 16 108

• TSA: Astrazeneca is the fastest growing company for the month followed by Janssen and for MAT Janssen has posted highest growth

• SSA: Wallace is the fastest growing company for the month followed by Raptakos, while for MAT Pharmed is the fastest growing company

IQVIA TSA & SSA Dataset Aug'22 12

 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Aug'22 (in comparison to Jul’22), among the In the month of Aug'22 (in comparison to Jul’22), among the
Top 25 companies Top 25 companies
• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%
• Emcure*, IPCA & Micro* 1 rank each to reach 14th, 16th & 18th • Macleods, Emcure* & Eris* gained 1 rank each to reach 6th,
positions 15th & 24th positions, respectively
• Macleods improved by 3 ranks to reach 6th position

As per MAT Aug'22 (in comparison to Jul’22), among the Top As per MAT Aug'22 (in comparison to Jul’22), among the
25 companies Top 25 companies
• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%
• All companies maintained their ranks except Zydus*, IPCA & • All companies maintained their rank except Macleods &
Eris* gained 1 rank each to reach 11th, 17th & 24th for Mat Aug’22 Alembic gained 1 rank each to reach 7th & 19th positions,
respectively

IQVIA TSA & SSA Dataset Aug’22 13

 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

41 0.46 0.20
AUGMENTIN 81 RYZODEG 35 33
-1 0.41 0.20
MIXTARD 72 ZERODOL-SP 35 18
17 0.37 0.20
GLYCOMET-GP 64 DUOLIN 35 15
Top 1-10

Top 21-30
-3 0.34 0.20
MONOCEF 59 RANTAC 35 8
30 0.33 0.20
FORACORT 58 ULTRACET 35 17
27 0.31 0.19
CLAVAM 55 ACILOC 34 25
0 0.30 0.19
CALPOL 52 TELMA 34 27
17 0.29 0.19
BETADINE 50 ZIFI 34 10
-2 0.28 0.19
LANTUS 50 MIKACIN 34 21
9 0.28 0.19
DOLO 49 MOXIKIND-CV 34 24
0.28 33 12 0.19
PAN 49 38 CEFTUM
THYRONORM 46 18 0.26 MANFORCE 33 42 0.19
0.25 26 0.18
Top 11-20

LIV-52 44 3 TAXIM-O 32

Top 31-40
AZITHRAL 43 4 0.25 ZINCOVIT 32 16 0.18
DEXORANGE 42 -5 0.24 VOLINI 32 7 0.18
UDILIV 41 20 0.23 JANUMET 31 -12 0.18
PAN-D 40 33 0.23 LEVIPIL 31 15 0.18
NOVOMIX 37 -6 0.21 DUPHASTON 31 17 0.18
SHELCAL 37 17 0.21 BUDECORT 31 32 0.18
T-BACT 36 30 0.20 ZERODOL-P 31 3 0.18

• Augmentin is the topmost brand with 81 Crs of sales & MS of ~0.46% for the month

• Among top 10 brands Augmentin has shown highest growth followed by Foracort for the month

IQVIA TSA & SSA Dataset Aug'22 14

 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Aug'22 Month (in comparison to Jul’22 Month)
• Augmentin has gained No 1 position at month level with a growth of 41%
• Similarly, Azithral & Novomix gained 1 rank each to secure 14th and 18th position, respectively
• Amongst the top 10 Brands, highest growth is observed by Augmentin & Foracort with a growth of 41% & 30% respectively
• Clavam gained 3 rank to secure 6th position respectively with a growth of 27%
• Ryzodeg gained 4 ranks to secure 21st position with a growth of 33%
• Monocef & Calpol gained 6 ranks to secure 4th and 7th position with a growth of -3% and 0.4% respectively
• Duolin gained 8 ranks to secure 23rd position with a growth of 15%
• Dolo gained 11 ranks to secure 10th position with a growth of 9%

IQVIA TSA & SSA Dataset Jul’21

IQVIA TSA & SSA Dataset Aug'22 15
 Indian / MNC trends % Growth Over Same Month Last Year
25 23
Indian
20
14 14 14 MNC
15 14 10
11 11 10 9
Month Growth

10 8
5 8 5
4 4 4
5 7 1
0 2
-6
-5 -8
-10
-10
SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22

Value (Rs. Crs)

Indian MNC

16,546 15,771 15,126 15,168 16,009 13,447 14,360 15,969 15,591 15,728 16,665 17,575
Share in IPM

13,696 13,026 12,412 12,443 13,244 11,033 11,736 13,131 12,825 12,957 13,806 14,544

2,850 2,745 2,714 2,725 2,765 2,414 2,624 2,839 2,766 2,771 2,859 3,030

SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22

• Indian companies has registered growth of 10% whereas MNC’s registered a growth of 8% for the month

IQVIA TSA & SSA Dataset Aug'22 16

 Acute / Chronic Trends
27
30
25 ACUTE
20 15 CHRONIC
14 13 14
13 12
15 10 11 12 10
10 9 10
Growth (%)

9 8 8
10
5 53 2 1 2
0
-5
-11
-10
-15 -15
SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22

Gwth %
10% 1% 26% 4% 11%
Top 5 TC 4s

269 254 235

Value (Rs 198 184
Crs)

GLIMEPIRIDE+METFORM. COUGH PREP. ETHICALS AMOXY. & CLAV. SOLIDS INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 64 DRL 37 GSK* 57 ABBOTT* 144 APEX 33

LUPIN 29 GLENMARK 35 ALKEM* 39 LUPIN 27 ALKEM 31

SUN* 27 FRANCO 25 MANKIND 33 CIPLA 11 SUN* 24

• Acute has shown growth of 8% whereas chronic is at 12% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Aug'22 17
 Top Therapy Trends
TSA

Value_AUG'22 (Rs. Crs) % Gwth SPLY Value_AUG'22 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 103 12 J01C0G AMOXY. & CLAV. SOLIDS 235 26

C02C04 TELMISARTAN 92 15 J01D0C CEFTRIAXONE INJECTABLS 152 5

7 J01N01 MEROPENEM 116 12

Anti-Infectives
C10A03 ATORVASTATIN 79
C02F06 AMLODIPINE+TELMISARTAN 75 17 J01F04 AZITHROMYCIN ORAL SOLIDS 110 1
Cardiac

C02G0H TELMISARTAN + HCT 66 11 J01D0L CEFIXIME ORAL SOL. 107 38

B01A0E ENOXAPARIN 60 -13 J01C0H AMOXY. & CLAV. LIQUIDS 106 16

C01E03 METOPROLOL 58 7 J01D0I CEFUROXIME ORAL SOLIDS 94 17

C02F02 ATENOLOL+AMLODIPINE 53 16 J01D0Z CEFTRIAXONE+SULBACTAM 88 16

C01D0B CILNIDIPINE 52 4 J01D0V CEFPODOXIME SOLIDS 86 7

C02F0I METOPROLOL+TELMISARTAN 50 39 J01K03 AMIKACIN 79 26

A02B0Q PANTOPR.+ DOMPERID. 133 18 A10B0Q GLIMEPIRIDE+METFORM. 269 10

A02B0R RABEPRA.+ DOMPERID. 102 5 A10C03 INTER.-ACTING+FAST ACTING 198 4
A02B0A PANTOPRAZOLE SOLIDS 95 20 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 97 11
30

Anti Diabetic
A07L01 ORAL ELECTROLYTES 67 A10C05 LONG ACTING 89 6
A07K09 OTHERS 63 13 A10B0D METFORMIN + VILDAGLIPTIN 82 13
GI

A02B01 RANITIDINE ORAL SOLIDS 60 13 A10C01 FAST ACTING 68 6

A09A02 DIGEST. INC. ENZYME LIQUIDS 56 19 A10B0W PIOGLITAZ.+METFORM.+GLIM. 68 17
A02B0S ESOMEPR.+ DOMPERID. 54 4 A10B07 METFORMIN + SITAGLIPTIN 62 7
A02A05 ANTACID+ANTIFLATU.LIQ 50 12 A10B0O METFORMIN + TENELIGLIPTIN 53 -3
A06A07 MILK OF MAG AND COMB. 50 7 A10B12 DAPAGLIFLOZIN 44 30

• In Cardiac, Metoprolol+Telmisartan posted highest growth of 39%

• In AI, Cefixime oral sol has posted 38% growth which is highest amongst top therapy
• Pantopr.+ Domperid.is the top contributing subgroup in GI therapy value around 133 Cr with a growth of 18%
• In Anti diabetic, dapagliflozin subgroup has posted highest growth of 30%

IQVIA
IQVIA TSA &TSA & SSA
SSA Dataset Dataset
Aug'22 Aug’21 18
 Top Therapy Trends
TSA

Value_AUG'22 (Rs. Crs) % Gwth SPLY Value_AUG'22 (Rs. Crs) % Gwth SPLY

V06E01 FOOD SUPPLEMENTS 184 11 R05B01 COUGH PREP. ETHICALS 254 1

A11F02 MECOBALAMIN COMB. 102 8 R03B01 LEVOCETIRIZ.+MONTELU SOLD 107 13

RESPIRATORY
A12A04 CALCIUM + COLECALCI. SOLI. 101 12 R03C0R FORMOTERAL+BUDESONIDE 96 21

A11C02 PLAIN VIT.D 81 13 R05A02 COLD PREP. LIQUIDS 82 3

22
VMN

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 77 0 R05B05 LEVOSALBUTAMOL & COMB. 82

V06C01 INFANT FORMULAS 76 24 R05B03 CODEINE AND COMB. 52 2

A15A01 APPETITE STIMULANTS 53 3 R05A01 COLD PREP. SOLIDS 48 2

A12A01 CALCIUM ORAL SOLIDS 44 16 R05B07 CHLORPHNMN+DEXTROMETHRPHN 48 -1

V06E05 ADULT WELLNESS 44 4 R03C0S IPRATROPIUM + LEVOSALBU. 42 14

A11E0C WITH VIT.C SOLIDS 43 5 R03C0P SALMETEROL+FLUTICASONE 39 35

M02A01 NSAIDS 106 4 D02A01 EMOLLIENTS,PROTECTIVES 101 13

N02B05 PARACETAMOL ORAL SOLIDS 87 7 D01C03 ITRACONAZOLE 96 1
M05C02 CALCITRIOL COMB. 73 6 D11A09 OTH.DERMATOLOGICAL PREP. 53 17
M01A0G PARACE.+ACECLOF.+SERRAPE. 63 19 D01A02 LULICONAZOLE 46 24

Derma
N02B06 PARACETAMOL ORAL LIQUIDS 61 20 D06A08 MUPIROCIN 45 -5
Pain

N02B0K PARACETAMOL + TRAMADOL 58 4 D07D0C CLOBET+MICONAZOL+NEOMYCIN 30 5

M01A0U ACECLOFENAC + PARACETAMOL 50 37 D02C07 HYDROQU.+TRETI.+MOMETA. 29 0
M05B0C COLLAGEN COMB 47 13 D02B01 SUNSCREENS 28 38
N02B07 PARACETAMOL INJECTIONS 43 16 D16A0D OTH HAIR CARE PREPS. 27 12
M01A03 DICLOFENAC INJECTABLES 40 20 D02E01 MINOXIDIL 26 1

• In VMN therapy, food supplements is the top contributing subgroup with 184 Cr of sales posted growth of 11%
• In Respiratory market, cough prep is observed to be top contributing one with 254 Cr of sales posted growth of 1%
• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 191 Crs of sales with 7%,20% & 16% growth, respectively
• Emollients protectives registered highest sales of 101 Cr in derma market with 13% growth while the highest growth of 38% is observed in sunscreens

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Aug'22 19
Top Therapy Trends
TSA

Value_AUG'22 (Rs. Crs) Value_AUG'22 (Rs. Crs) % Gwth SPLY

% Gwth SPLY
16 B03A01 CONV.IRON SOLIDS 125 10
N03A0T LEVETIRACETAM 85
7 B03A02 CONV.IRON LIQUID 116 5
N06C02 ESCITALOPRAM+CLONAZEPAM 39
12 G03D03 PROGESTERONE 81 75
N07C01 BETAHISTINE 37
23 71 4
Neuro / CNS

G03D04 DYDROGESTERONE

Gynaec.
N03A0V GABAPENTIN + NORTRIPTYLIN 35
8 B03A03 CONV.IRON INJ. 68 17
N07A02 PREGABALIN+MECOBALAMIN 27
7 G03K02 MIFEPRISTONE+MISOPROSTOL 34 4
N03A04 SODIUM VALPROATE ORAL SOLIDS 26
11 G02C01 OTHER GYNAECO.PREP. 32 7
N03A0J OXCARBAZEPINE 25
14 G03G06 HUMAN MENOPAUSAL GONADOTROP. 26 10
N07A01 PREGABALIN 24
5 G03G05 HUMAN CHORIONIC GONADOTROP. 25 2
N03A0I NORTRIPTYLINE+PREGABALIN 24
3 G03D02 NORETHISTERONE 23 15
N03A0D CLONAZEPAM 20

• In Neuro therapy, levetiracetam is the top valued subgroup with 85 Crs of sales and 16% of growth
• In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~309 Cr of sales to the entire therapy
• Among the top gynae Therapies,Progesterone has posted highest growth of 75%

IQVIA
IQVIA TSATSA
& SSA&Dataset
SSAAug'22
Dataset Aug’21 20
 Key changes
PTR Changes (Top 50 brands) New Introduction

➢ 1296 new packs were Introduced in Aug’22

➢ Total number of SKUs with PTR changes in Aug’22 is 2131.
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Foracort, Liv-52, Pan, Clavam, Calpol, Azithral,
Zincovit, Mikacin, Budecort, T-bact, Pantop, Gemer & Gluconorm-G.

New Lab & Corporate Brand Transfer

➢ 67 Corporates & Labs were introduced in Aug’22 dataset ➢ 2 brand transfer from Abbott Healthcare to Unident Manufact. in Aug’22

➢ 1 brand transfer from Parke Davis to Mylan Pharma in Aug’22

➢ 5 brand transfer from Pfizer to Mylan Pharma in Aug’22

➢ 2 brand transfer from Pharmacia to Mylan Pharma in Aug’22

IQVIA TSA & SSA Dataset Aug'22

21
THANK YOU